EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
• Initiation of AERIAL trial accelerated by successful first close of Series A1 financing• LEU011 is first CAR-T candidate for the treatment of
RapidPulse Announces Patient Enrollment Initiated in Pivotal Ischemic Stroke Study
May 06, 2025 11:00 ET | Source: RapidPulse, Inc MIAMI, May 06, 2025 (GLOBE NEWSWIRE) — RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida